过度表达的mcl1通过调节cuproptosis减轻易怒肠综合征:查和验证
Taohong He1, Jian Kang2, Xiao Tang3
1Department of Proctology, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39, Shi-er-qiao Road, Jinniu District, Chengdu City, Sichuan Province, 610072, China.
Biochemical and biophysical research communications
|November 2, 2024
概括
这项研究揭示了骨髓细胞白血病1 (MCL1) 在刺激性肠综合征 (IBS) 中通过调节铜诱导的细胞死亡 (cuproptosis) 发挥关键作用. 抑制MCL1通过促进细胞生长和减少炎症来缓解IBS症状.
科学领域:
- 胃肠病学 胃肠病学
- 细胞生物学 细胞生物学
- 分子医学是分子医学.
背景情况:
- 刺激性肠综合征 (IBS) 是一种慢性胃肠疾病,其原因尚不清楚.
- 铜不平衡和cuproptosis,一种新的细胞死亡途径,是IBS病理生理学的新兴因素.
研究的目的:
- 为了调查与cuproptosis相关的基因在IBS中的作用.
- 识别和验证参与IBS病原和潜在治疗点的关键基因.
主要方法:
- 在IBS中与cuproptosis相关的差异表达基因的生物信息分析.
- 蛋白质与蛋白质相互作用网络分析以确定枢纽基因.
- 在实验室验证使用人结肠上皮细胞 (NCM460) 用脂多糖 (LPS) 和铜 (II) (CuCl2) 处理.
主要成果:
- 在IBS中确定了17个与cuproptosis相关的差异表达基因,其中6个枢纽基因包括骨髓细胞白血病1 (MCL1).
- 在NCM460细胞中MCL1的过度表达促进了细胞活力,增殖,并减少了炎症因素.
- 升级调节的MCL1抑制了关键的cuproptosis调节剂 (ferredoxin 1和lipoyl合成酶) 并抑制了apoptosis标记物 (Bax和caspase-3).
结论:
- cuproptosis与IBS的病理生理学有关.
- MCL1 是一个关键的cuproptosis相关基因,通过增强细胞生长,减少炎症和抑制cuproptosis来减轻IBS.
- MCL1代表了管理IBS的潜在治疗目标.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
137
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
137
Irritable Bowel Syndrome I: Introduction
251
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
251
Chronic Bowel Disorders: Introduction
390
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
390
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Drugs for Treatment of Diarrhea-Predominant IBS
149
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
149


